Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Centre for Mendelian Genomics, |
RCV001196681 | SCV001367312 | uncertain significance | Ehlers-Danlos syndrome, classic type, 2 | 2019-08-09 | criteria provided, single submitter | clinical testing | This variant was classified as: Uncertain significance. The available evidence on this variant's pathogenicity is insufficient or conflicting. |
Labcorp Genetics |
RCV002240824 | SCV001559471 | uncertain significance | Ehlers-Danlos syndrome, classic type, 1 | 2020-01-11 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamic acid with aspartic acid at codon 865 of the COL5A2 protein (p.Glu865Asp). The glutamic acid residue is highly conserved and there is a small physicochemical difference between glutamic acid and aspartic acid. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This variant has not been reported in the literature in individuals with COL5A2-related conditions. This variant is present in population databases (rs746155819, ExAC 0.002%). |
Gene |
RCV004761966 | SCV005373015 | uncertain significance | not provided | 2023-07-12 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; Not observed at significant frequency in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function |